Financial Comparison: Journey Medical (NASDAQ:DERM) and MediWound (NASDAQ:MDWD)

Journey Medical (NASDAQ:DERM) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.

Risk and Volatility

Journey Medical has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, MediWound has a beta of 0.16, suggesting that its stock price is 84% less volatile than the S&P 500.

Valuation and Earnings

This table compares Journey Medical and MediWound”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$64.68 million	2.65	-$11.43 million	($0.37)	-16.81
MediWound	$16.96 million	10.95	-$23.88 million	($2.26)	-6.39

Journey Medical has higher revenue and earnings than MediWound. Journey Medical is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

7.3% of Journey Medical shares are owned by institutional investors. Comparatively, 46.8% of MediWound shares are owned by institutional investors. 15.0% of Journey Medical shares are owned by insiders. Comparatively, 9.2% of MediWound shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Journey Medical and MediWound’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Journey Medical	-14.82%	-35.57%	-10.88%
MediWound	-180.30%	-67.22%	-31.87%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Journey Medical and MediWound, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1	1	2	0	2.25
MediWound	1	1	2	0	2.25

Journey Medical presently has a consensus target price of $13.00, suggesting a potential upside of 109.00%. MediWound has a consensus target price of $34.00, suggesting a potential upside of 135.29%. Given MediWound’s higher possible upside, analysts clearly believe MediWound is more favorable than Journey Medical.

Summary

Journey Medical beats MediWound on 8 of the 12 factors compared between the two stocks.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.